Foley Represents TCGX in $30M Private Placement Financing in Nektar Therapeutics

Foley & Lardner LLP represented TCG Crossover (“TCGX”) in the $30 million private placement financing in Nektar Therapeutics, a biotechnology company developing medicines for the treatment of auto-immune disorders. Nektar Therapeutics is a biotechnology company with a wholly owned R&D pipeline of investigational medicines in immunology and oncology as well as a portfolio of approved […]
A Look at the Venture Capital Landscape in Q1 2024

With the first quarter of 2024 behind us, analysts are now taking a look at the dealmaking landscape so far this year. CB Insights has released their State of Venture Q1’24 report, showing a “mixed bag” for VC dealmaking to start the year. Their data shows dealmaking dropping to a 7-year low in Q1. It was also […]